CLAIMS

1. An oligomeric compound of 8 – 35 nucleotides in length, comprising three regions:
   i) a first region (region A), which is an antisense oligomer comprising 7 – 26 contiguous nucleotides complementary to a nucleic acid target, wherein the first region comprises at least one nucleoside analog and wherein the internucleoside linkages of the first region comprise at least 50% internucleoside linkage other than phosphodiester;
   ii) a second region (region B) which comprises between 1 – 10 nucleotides, which is covalently linked to the 5' or 3' nucleotide of the first region, such as via a internucleoside linkage group such as a phosphodiester linkage, wherein either
      a. the internucleoside linkage between the first and second region is a phosphodiester linkage and the nucleoside of the second region adjacent to the first region is either DNA or RNA; and/or
      b. at least 2 nucleosides of the second region are phosphodiester linked DNA or RNA nucleosides;
   iii) a third region which comprises a conjugate moiety, a targeting moiety, or a blocking moiety, wherein the third region is covalent linked to the second region.

2. The oligomeric compound according to claim 1, wherein the internucleoside linkages of the first region comprise at least 75%, such as at least 90%, such as 100% internucleoside linkages other than phosphodiester.

3. The oligomeric compound according to claim 1 or 2, wherein the internucleoside linkages other than phosphodiester are selected from the group consisting of phosphorothioate, phosphorodithioate and boranophosphate.

4. The oligomeric compound according to any one of claims 1 – 3, wherein the nucleic acid target is selected from the group consisting of a microRNA, a mRNA, a lncRNA (long non-coding RNA), a snRNA, snoRNA, and a viral RNA.

5. The oligomeric compound according to any one of claims 1 - 4, wherein the oligomeric compound, such as the first region, comprises a gapmer, a mixmer, or a totalmer.

6. The oligomeric compound according to any one of claims 1 - 5, wherein the oligomeric compound, such as the first region, comprises at least one bicyclic nucleotide analogue (LNA).

7. The oligomeric compound according to any one of claims 1 – ~~6~~6, wherein the first region and the second region form a contiguous nucleotide sequence.

8. The oligomeric compound according to any one of claims 1 – 7, wherein the second region is 5' to the first region.

9. The oligomeric compound according to any one of claims 1 – 7, wherein the second region is 3' to the first region.

10. The oligomeric compound according to any one of claims 1 – 9, wherein the second region comprises at least two, such as at least three consecutive nucleoside units, selected from the group of DNA and RNA units, which may be linked by phosphodiester linkages.

11. The oligomeric compound according to any one of claims 1 – 10, wherein the second region is covalently linked to the third region at the terminal nucleoside of the second region (i.e. the 3' or 5' terminus, depending on the position of the first region).

12. The oligomeric compound according to any one of claims 1 – 11, wherein the third region comprises a non-nucleotide moiety, such as a conjugate group, such as a sterol, for example cholesterol, or a carbohydrate, such as GalNac/GalNac cluster.

13. The oligomeric compound according to claim 12, wherein the third region comprises a moiety selected from the group consisting of: a lipophilic group (e.g. a lipid, a fatty acid, a sterol), a protein, a peptide, an antibody or fragment thereof, a polymer, a reporter group, a dye, a receptor ligand, a small molecule drug, a prodrug, and a vitamin.

14. The oligomeric compound according to any one of claims 1 – 11, wherein the third region comprises a nucleic acid or polymer thereof, such as an aptamer, or a blocking nucleotide sequence.

15. The oligomeric compound according to any one of claims 1 – 14, wherein the third region comprises a targeting group.

16. The oligomeric compound according to any one of claims 1 – 11, wherein the third region comprises an activated group.

17. The oligomeric compound according to any one of claims 1 – 16, wherein the second and third regions are covalently joined by a linker group.

18. The oligomeric compound according to any one of claims 1 – 17, wherein the linker group between the second and third regions comprises a group selected from phosphodiester, a phosphorothioate, and phosphorodithioate or a boranophosphate group, such as a phosphodiester group.

19. A pharmaceutical composition comprising the oligomeric compound of any one of claims 1-18, and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.

20. The oligomeric compound according to any one of claims 1-18 for use in the inhibition of a nucleic acid target in a cell.

21. The oligomeric compound according to any one of claims 1-18 for use in medicine.

22. The oligomeric compound according to any one of claims 1-18 for use in the treatment of a medical disease or disorder.

23. The use of the oligomeric compound according to any one of claims 1-18 for the preparation of a medicament for the treatment of a disease or disorder, such as a metabolic disease or disorder.

24. A method of synthesizing an oligomeric compound comprising a first region, a second region and a third region, and optionally a linker region (Y), as defined in claims 1-18, said method comprising
either:

a) a step of providing an oligonucleotide synthesis support to which one of the following is attached:
   i) a linker group (-Y-)

ii) a group (X-) selected from the group consisting of a conjugate, a targeting group or a blocking group,

iii) an -Y – X group

and

b) a step of oligonucleotide synthesis of region B followed by region A,

or:

c) a step of oligonucleotide synthesis of a first region (A) and a second region (B), wherein the synthesis step is followed by

d) a step of adding a third region

i) a linker group (-Y-)

ii) a group (X-) selected from the group consisting of a conjugate, a targeting group or a blocking group

iii) an -Y – X group

followed by

e) the cleavage of the oligomeric compound from the support

wherein, optionally said method further comprises a further step

wherein the third region is a linker group (Y), the step of adding a conjugate, a blocking, or targeting group to the linker group (Y) are performed either prior to or subsequent to cleavage of the oligomeric compound from the oligonucleotide synthesis support.

25. A method of treatment of a disease or disorder in a subject in need of treatment, said method comprising the steps of administering a pharmaceutical composition comprising the oligomeric compound according to any one of claims 1-18 to said subject in a therapeutically effective amount.

26. A method of inhibiting the expression of a target gene in a cell, said method comprising administering the oligomeric compound according to any one of claims 1-18 to a cell which is expressing said target gene, suitably in an amount effective to reduce the expression of the target gene in said cell.